quinuclidines has been researched along with aprepitant in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (26.09) | 29.6817 |
| 2010's | 45 (65.22) | 24.3611 |
| 2020's | 6 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Hussar, DA | 1 |
| Viale, PH | 1 |
| Ihbe-Heffinger, A; Lordick, F; Peschel, C | 1 |
| Cullen, MT; Gallagher, SC; Hunt, TL; Shah, AK | 1 |
| Schwartzberg, L | 1 |
| Navari, RM; Province, PS | 1 |
| Fatigoni, S; Roila, F | 1 |
| Padezanin, S | 1 |
| Cartmell, A; Charu, V; Ferguson, S; Ginkel, A; Grote, T; Hajdenberg, J | 1 |
| Herrstedt, J | 1 |
| Wilkes, G | 1 |
| Eberhart, LH; Kranke, P; Schuster, F | 1 |
| Hamaguchi, T | 1 |
| Herrington, JD; Jaskiewicz, AD; Song, J | 1 |
| Ellebaek, E; Herrstedt, J | 1 |
| Burdette-Radoux, S; Dugan, M; Grunberg, SM; Muss, H; Siebel, M; Weisberg, T; Wood, M | 1 |
| Navari, RM | 1 |
| Eberhart, LH; Kranke, P; Wallenborn, J | 1 |
| Altavilla, A; Cimadon, B; Cortesi, E; D'Antoni, I; De Luca, C; De Sanctis, R; Del Signore, E; Di Seri, M; Gamucci, T; Gori, B; Grande, R; Lapadula, V; Longo, F; Mansueto, G; Quadrini, S; Stumbo, L | 1 |
| Apfel, CC; George, E; Hornuss, C | 1 |
| Balu, S; Buchner, D; Jackson, J; Jain, G; Schwartzberg, L | 1 |
| Basch, E; Chesney, M; Clark-Snow, RA; Feyer, PC; Flaherty, AM; Freundlich, B; Hesketh, PJ; Kris, MG; Lyman, GH; Morrow, G; Prestrud, AA; Rao, KV; Schwartz, RN; Somerfield, MR | 1 |
| Barzal, J; Gawronski, K; Mlot, B; Oborska, S; Pielichowski, W; Rzepecki, P; Wasko-Grabowska, A | 1 |
| Hiura, K; Komori, H; Sato, H; Suzuki, C; Yamamoto, M | 1 |
| Hesketh, PJ; Sanz-Altamira, P | 1 |
| Gao, HF; Liang, Y; Wu, HY; Zhang, DS; Zhou, NN | 1 |
| Dakhil, SR; Heckler, CE; Kuebler, JP; Mohile, SG; Morrow, GR; Roscoe, JA; Wade, JL | 1 |
| Gray, SE; Nagy, CK; Navari, RM | 1 |
| Iwashima, A; Kagamu, H; Kobayashi, O; Makino, M; Miura, S; Miyao, H; Narita, I; Okajima, M; Sato, K; Tanaka, H; Tanaka, J; Watanabe, S; Yokoyama, A; Yoshizawa, H | 1 |
| Hatake, K; Ito, Y; Nakayama, Y; Takahashi, S; Tanabe, M | 1 |
| Berger, MJ; Blazer, MA; Crawford, BS; Flynn, JM; Griffith, NL; Layman, RM; Lustberg, MB; Mrozek, E; Phillips, GS; Ramaswamy, B; Shapiro, CL; Wenzell, CM; Wesolowski, R | 1 |
| Goto, H; Myojo, T; Osawa, H | 1 |
| Abhyankar, S; Aljitawi, OS; Deauna-Limayo, D; Ganguly, S; McGuirk, JP; Wick, JA | 1 |
| Akashi, K; Arita, S; Ariyama, H; Baba, E; Komoda, M; Kumagai, H; Kusaba, H; Nagata, K; Nakano, M; Okumura, Y; Takaishi, S; Tamura, S; Uchida, M | 1 |
| Arai, Y; Habuchi, T; Hamada, S; Hinotsu, S; Kamba, T; Kawai, K; Kawakami, K; Narita, S; Nishiyama, H; Ogawa, O; Yamada, S | 1 |
| Abe, M; Furuya, K; Hasegawa, K; Hirashima, Y; Itamochi, H; Ito, K; Kai, K; Kuritani, K; Matoda, M; Nasu, K; Otsuki, T; Sato, S; Takano, M; Takeshima, N; Terao, K; Tsubamoto, H | 1 |
| Fukahori, S; Fukuda, Y; Kitazaki, T; Kohno, S; Nakamura, Y; Oyanagi, K; Soda, H | 1 |
| Baek, CW; Choi, GJ; Jung, YH; Kang, H; Kim, JY; Moon, HY; Park, SG; Shin, HY; Woo, YC | 1 |
| Wang, SY; Yang, ZJ; Zhang, L | 1 |
| Aoki, Y; Hayashi, K; Higuchi, T; Igarashi, K; Inatani, H; Kato, T; Kimura, H; Nishida, H; Shimozaki, S; Shirai, T; Takeuchi, A; Tanzawa, Y; Tsuchiya, H; Yamamoto, N | 1 |
| Bianchi, S; Cappelli, S; De Luca Cardillo, C; Detti, B; Fambrini, M; Francolini, G; Furfaro, IF; Livi, L; Mangoni, M; Meacci, F; Meattini, I; Muntoni, C; Nori, J; Orzalesi, L; Scoccianti, S; Scotti, V | 1 |
| Angelelli, L; Ballatori, E; Caserta, C; Cavanna, L; Ciuffreda, L; Colantonio, I; Fasola, G; Fatigoni, S; Fava, S; Ionta, MT; Licitra, L; Massidda, B; Mirabile, A; Palladino, MA; Roila, F; Ruggeri, B; Tocci, A; Zerilli, F | 1 |
| Horita, H; Hotta, H; Kato, R; Kitamura, H; Kunishima, Y; Masumori, N; Takahashi, A; Takei, F | 1 |
| Abe, M; Hihara, H; Hirakawa, T; Hirashima, Y; Ichikawa, Y; Ito, K; Itonaga, Y; Kado, N; Kasamatsu, Y; Komeda, S; Kuji, S; Miyagi, K; Murakami, J; Nasu, K; Takahashi, N; Takekuma, M; Tanaka, A | 1 |
| Fujiwara, S; Kanemura, M; Ohmichi, M; Sasaki, H; Terai, Y; Tsunetoh, S | 1 |
| Enomoto, T; Katoh, H; Kikuchi, M; Kosaka, Y; Kuranami, M; Minatani, N; Nishimiya, H; Sato, T; Sengoku, N; Tanino, H; Waraya, M; Watanabe, M | 1 |
| Fujimura, T; Fushida, S; Kadoya, N; Kaji, M; Kinami, S; Kinoshita, J; Nezuka, H; Ohta, T; Ohyama, S; Oyama, K; Takai, Y; Takeda, T; Tsuji, K; Tsukada, T; Tsukioka, Y; Yabushita, K | 1 |
| Hou, F; Le, Q; Li, H; Li, W; Liu, S; Shi, Q; Zheng, L; Zong, S | 1 |
| Hashizume, J; Higuchi, N; Kitahara, T; Kodama, Y; Matsunaga, N; Nakamura, T; Sakamoto, T; Sasaki, H; Sato, K; Yamaguchi, K | 1 |
| Liaw, CC; Wu, CE; Yang, CK | 1 |
| Azuma, M; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Sasaki, T; Tanabe, S; Wada, T; Yano, T | 1 |
| Hanawa, S; Matsuoka, A; Mitsuhashi, A; Nishikimi, K; Shozu, M; Tate, S; Uno, T; Usui, H | 1 |
| Gralla, R; Jordan, K; Kashef, K; Rizzi, G | 1 |
| Choi, EK; Jeon, Y; Kim, DG | 1 |
| Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Takano, S; Yamamoto, T | 1 |
| Fang, W; Hong, S; Huang, Y; Kang, S; Luo, Y; Sheng, J; Yang, Y; Zhan, J; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H; Zhou, N | 1 |
| Ishikawa, T; Isoda, A; Komatsu, F; Manaka, A; Matsumoto, M; Miyazawa, Y; Negishi, Y; Oosawa, N; Saito, R; Sawamura, M | 1 |
| Furukawa, N; Ito, F | 1 |
| Isobe, T; Iwamoto, Y; Kaneko, M; Kenmotsu, H; Kikugawa, M; Koizumi, S; Mori, K; Murakami, H; Naito, T; Nakashima, K; Nishiyama, F; Omori, S; Ono, A; Takahashi, T; Wakuda, K; Yokoyama, K | 1 |
| Ishiguro, T; Ogishima, D; Ota, T; Sugimori, Y; Ujihira, T | 1 |
| Arai, T; Hashimoto, H; Iwasa, S; Minato, K; Nagashima, K; Nakao, M; Nakayama, T; Ohyanagi, F; Sakai, H; Shimada, Y; Suzuki, K; Takeda, K; Takiguchi, T; Terakado, H; Yamamoto, N; Yanai, T | 1 |
| Aapro, M; Chang, J; Chessari, S; Dechaphunkul, A; Feng, J; Jordan, K; Lanzarotti, C; Lu, S; Wang, D; Zhang, L | 1 |
| Borroni, ME; Hansen, V; Jordan, K; Karthaus, M; Rizzi, G; Rossi, G; Rugo, HS; Schwartzberg, L | 1 |
| Anzai, Y; Ishida, Y; Kawahara, F; Kimoto, S; Kouuchi, A; Saito, N; Saito-Inoue, K; Watanabe, T | 1 |
| Bachet, JB; Bourgeois, H; Brocard, F; Chauffert, B; Debourdeau, P; Lefeuvre-Plesse, C; Leheurteur, M; Mayeur, D; Scotté, F; Simon, H; Wagner, JP; Zelek, L | 1 |
| Cao, Y; Cheng, X; Fu, C; Hong, X; Kang, J; Ma, J; Meng, Y; Shao, G; Shi, Y; Wang, L; Wang, X; Wang, Y; Yan, Z; Zhang, Q | 1 |
| Aapro, M; Eriksson, J; Lezzi, C; Nilsson, J; Piovesana, V; Turini, M | 1 |
| Egawa, T; Hayashi, T; Kawada, K; Matsuo, K; Nakano, T; Shimokawa, M; Uchiyama, M | 1 |
| Aapro, M; Navari, R; Scotté, F; Zelek, L | 1 |
15 review(s) available for quinuclidines and aprepitant
| Article | Year |
|---|---|
Integrating aprepitant and palonosetron into clinical practice: a role for the new antiemetics.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Humans; Isoquinolines; Morpholines; Nausea; Palonosetron; Practice Guidelines as Topic; Quinuclidines; Vomiting | 2005 |
[Antiemetic prophylaxis in the chemotherapy of gastrointestinal tumours].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Drug Therapy, Combination; Gastrointestinal Neoplasms; Humans; Isoquinolines; Morpholines; Nausea; Palonosetron; Premedication; Quinuclidines; Treatment Outcome; Vomiting | 2005 |
Chemotherapy-induced nausea and vomiting: state of the art in 2006.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Humans; Isoquinolines; Medical Oncology; Morpholines; Nausea; Neoplasms; Palonosetron; Quality of Life; Quinuclidines; Vomiting | 2006 |
Emerging drugs for chemotherapy-induced emesis.
Topics: Antiemetics; Antineoplastic Agents; Antipsychotic Agents; Aprepitant; Benzodiazepines; Brain; Dexamethasone; Drug Therapy, Combination; Gastrointestinal Tract; Humans; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Receptors, Neurokinin-1; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vagus Nerve; Vomiting | 2006 |
New antiemetic drugs.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Therapy, Combination; Humans; Isoquinolines; Medical Oncology; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin Antagonists; Vomiting | 2006 |
[Medical treatment of chemotherapy-induced nausea and vomiting].
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Dexamethasone; Drug Interactions; Drug Therapy, Combination; Evidence-Based Medicine; Ghrelin; Glucocorticoids; Granisetron; Humans; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Peptide Hormones; Practice Guidelines as Topic; Quinuclidines; Serotonin Antagonists; Vomiting | 2007 |
Recent advances, trends and economic considerations in the risk assessment, prevention and treatment of postoperative nausea and vomiting.
Topics: Algorithms; Antiemetics; Aprepitant; Dexamethasone; Drug Therapy, Combination; Humans; Isoquinolines; Morpholines; Neurokinin-1 Receptor Antagonists; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Risk Assessment; Serotonin Antagonists | 2007 |
[Gastrointestinal complication of cancer chemotherapy].
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Diarrhea; Humans; Isoquinolines; Morpholines; Nausea; Palonosetron; Quinuclidines; Risk; Serotonin Antagonists; Stomatitis; Vomiting | 2007 |
Optimizing antiemetic therapy in multiple-day and multiple cycles of chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Dopamine D2 Receptor Antagonists; Drug Administration Schedule; Humans; Isonipecotic Acids; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2008 |
Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Clinical Trials, Phase III as Topic; Humans; Isoquinolines; Morpholines; Nausea; Palonosetron; Piperazines; Piperidines; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
Neurokinin-1 and novel serotonin antagonists for postoperative and postdischarge nausea and vomiting.
Topics: Ambulatory Surgical Procedures; Anesthesia; Antiemetics; Aprepitant; Humans; Isoquinolines; Morpholines; Neurokinin-1 Receptor Antagonists; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Serotonin Antagonists | 2010 |
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Administration Schedule; Humans; Infusions, Intravenous; Isoquinolines; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Radiotherapy; Serotonin Antagonists; Surveys and Questionnaires; Vomiting | 2011 |
Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Dexamethasone; Emetics; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Vomiting | 2014 |
Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Granisetron; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Network Meta-Analysis; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Spiro Compounds; Treatment Outcome; Vomiting | 2016 |
Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Therapy, Combination; Humans; Isoquinolines; Morpholines; Nausea; Network Meta-Analysis; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2017 |
35 trial(s) available for quinuclidines and aprepitant
| Article | Year |
|---|---|
Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiemetics; Aprepitant; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Isoquinolines; Male; Morpholines; Palonosetron; Quinuclidines | 2005 |
Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2006 |
Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Double-Blind Method; Drug Therapy, Combination; Humans; Isoquinolines; Morpholines; Nausea; Palonosetron; Pilot Projects; Quinuclidines; Vomiting | 2008 |
Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Time Factors; Vomiting | 2009 |
A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carmustine; Cytarabine; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Melphalan; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Transplantation, Autologous; Treatment Outcome; Vomiting | 2011 |
Aprepitant, dexamethasone, and palonosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Palonosetron; Pilot Projects; Quinuclidines; Vomiting | 2012 |
Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Constipation; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Headache; Hiccup; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Palonosetron; Prospective Studies; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting; Young Adult | 2013 |
Prevention of delayed nausea: a University of Rochester Cancer Center Community Clinical Oncology Program study of patients receiving chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Granisetron; Humans; Intention to Treat Analysis; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Prochlorperazine; Quinuclidines; Serotonin Antagonists | 2012 |
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Female; Humans; Isoquinolines; Male; Metoclopramide; Middle Aged; Morpholines; Nausea; Neoplasms; Olanzapine; Palonosetron; Quinuclidines; Vomiting | 2013 |
The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome; Vomiting | 2013 |
A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Dexamethasone; Female; Granisetron; Humans; Isoquinolines; Middle Aged; Morpholines; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome; Vomiting | 2015 |
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Ondansetron; Palonosetron; Pilot Projects; Prospective Studies; Quinuclidines; Vomiting | 2013 |
Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Female; Humans; Isoquinolines; Male; Morpholines; Nausea; Neoplasms, Germ Cell and Embryonal; Palonosetron; Quinuclidines; Testicular Neoplasms; Vomiting | 2014 |
Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quality of Life; Quinuclidines; Vomiting | 2014 |
Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Carboplatin; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Japan; Lung Neoplasms; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Salvage Therapy; Surveys and Questionnaires; Treatment Outcome; Vomiting | 2015 |
Palonosetron and aprepitant for the prevention of postoperative nausea and vomiting in patients indicated for laparoscopic gynaecologic surgery: a double-blind randomised trial.
Topics: Adult; Analgesia, Patient-Controlled; Antiemetics; Aprepitant; Double-Blind Method; Female; Gynecologic Surgical Procedures; Humans; Isoquinolines; Laparoscopy; Middle Aged; Morpholines; Pain Measurement; Pain, Postoperative; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Young Adult | 2014 |
Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-da
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Bone Neoplasms; Cross-Over Studies; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Sarcoma; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting; Young Adult | 2015 |
Aprepitant as prophylaxis of chemotherapy-induced nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for adjuvant breast cancer.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dexamethasone; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2015 |
Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study.
Topics: Activities of Daily Living; Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Isoquinolines; Italy; Male; Metoclopramide; Middle Aged; Morpholines; Nausea; Palonosetron; Quality of Life; Quinuclidines; Risk Factors; Time Factors; Treatment Outcome; Vomiting; Young Adult | 2015 |
Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Olanzapine; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vomiting | 2016 |
Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Cross-Over Studies; Diet; Drug Administration Schedule; Female; Genital Neoplasms, Female; Granisetron; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Paclitaxel; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2015 |
Phase II randomized, controlled trial of 1 day versus 3 days of dexamethasone combined with palonosetron and aprepitant to prevent nausea and vomiting in Japanese breast cancer patients receiving anthracycline-based chemotherapy.
Topics: Adult; Aged; Anthracyclines; Antiemetics; Antineoplastic Agents; Aprepitant; Breast Neoplasms; Dexamethasone; Female; Humans; Isoquinolines; Japan; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Vomiting | 2016 |
Aprepitant, granisetron, and dexamethasone versus palonosetron and dexamethasone for prophylaxis of cisplatin-induced nausea and vomiting in patients with upper gastrointestinal cancer: a randomized crossover phase II trial (KDOG 1002).
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Cross-Over Studies; Dexamethasone; Esophageal Neoplasms; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Serotonin Antagonists; Stomach Neoplasms; Vomiting | 2016 |
Efficacy of palonosetron plus aprepitant in preventing chemoradiotherapy-induced nausea and emesis in patients receiving daily low-dose cisplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a phase II study.
Topics: Adult; Aged; Aprepitant; Chemoradiotherapy; Cisplatin; Drug Therapy, Combination; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Uterine Cervical Neoplasms; Vomiting | 2016 |
Efficacy benefit of an NK1 receptor antagonist (NK1RA) in patients receiving carboplatin: supportive evidence with NEPA (a fixed combination of the NK1 RA, netupitant, and palonosetron) and aprepitant regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Palonosetron; Pyridines; Quinuclidines; Receptors, Neurokinin-1 | 2016 |
Comparison of the Prophylactic Antiemetic Efficacy of Aprepitant Plus Palonosetron Versus Aprepitant Plus Ramosetron in Patients at High Risk for Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Prospective Randomized-controlled Tri
Topics: Adolescent; Adult; Aged; Antiemetics; Aprepitant; Benzimidazoles; Cholecystectomy, Laparoscopic; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Isoquinolines; Middle Aged; Morpholines; Palonosetron; Postoperative Nausea and Vomiting; Prospective Studies; Quinuclidines; Treatment Outcome; Young Adult | 2016 |
Palonosetron, aprepitant, and dexamethasone for prevention of nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: A phase II study.
Topics: Adult; Aged; Antiemetics; Aprepitant; Dexamethasone; Drug Therapy, Combination; Humans; Isoquinolines; Melphalan; Middle Aged; Morpholines; Multiple Myeloma; Myeloablative Agonists; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Transplantation, Autologous; Treatment Outcome | 2017 |
A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Olanzapine; Palonosetron; Quinuclidines; Thoracic Neoplasms; Vomiting | 2017 |
A phase II randomised study to evaluate the efficacy of aprepitant plus palonosetron for preventing delayed-phase CINV associated with TC therapy in gynaecological cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Drug Therapy, Combination; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Outcome Assessment, Health Care; Paclitaxel; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2017 |
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Neoplasms; Olanzapine; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2018 |
A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving h
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Asia; Cisplatin; Dexamethasone; Double-Blind Method; Drug Combinations; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Pyridines; Quinuclidines; Vomiting | 2018 |
Fixed combination of oral NEPA (netupitant-palonosetron) for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double-blind phase III studie
Topics: Administration, Oral; Anthracyclines; Antiemetics; Aprepitant; Cyclophosphamide; Dexamethasone; Double-Blind Method; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Male; Middle Aged; Palonosetron; Pyridines; Quinuclidines; Treatment Outcome | 2019 |
[Efficacy of Antiemetic Therapy with Aprepitant, Palonosetron, and Dexamethasone in Patients Receiving Oxaliplatin-Based Chemotherapy].
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Humans; Japan; Oxaliplatin; Palonosetron; Quinuclidines; Vomiting | 2020 |
A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Topics: Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents; Aprepitant; Double-Blind Method; Humans; Isoquinolines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Vomiting | 2021 |
Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Topics: Anthracyclines; Antiemetics; Antineoplastic Agents; Aprepitant; Cyclophosphamide; Dexamethasone; Drug Combinations; Female; Humans; Isoquinolines; Male; Nausea; Prospective Studies; Quinuclidines; Vomiting | 2023 |
19 other study(ies) available for quinuclidines and aprepitant
| Article | Year |
|---|---|
New drugs 04. Part III.
Topics: Adrenergic alpha-Antagonists; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antineoplastic Agents; Aprepitant; Boronic Acids; Bortezomib; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Glucans; Glucose; Glucosylceramidase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Icodextrin; Immunosuppressive Agents; Isoquinolines; Morpholines; Nurse's Role; Omalizumab; Palonosetron; Patient Education as Topic; Pyrazines; Pyrimidines; Quinazolines; Quinuclidines; Rosuvastatin Calcium; Sulfonamides | 2004 |
Applying new data to manage CINV: achieving optimal outcomes through a comprehensive care model.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Comprehensive Health Care; Evidence-Based Medicine; Humans; Isoquinolines; Models, Organizational; Morpholines; Nausea; Neoplasms; Nurse's Role; Oncology Nursing; Palonosetron; Patient Care Team; Practice Guidelines as Topic; Quinuclidines; Total Quality Management; Vomiting | 2006 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipation; Diarrhea; Drug Interactions; Dyspepsia; Fatigue; Fever; Granisetron; Headache; Hiccup; Humans; Indoles; Injections, Intravenous; Isoquinolines; Morpholines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Vomiting | 2007 |
[Postoperative nausea and vomiting--what's new in anti-emetic pharmacotherapy?].
Topics: Antiemetics; Aprepitant; Humans; Isoquinolines; Morpholines; Neurokinin-1 Receptor Antagonists; Palonosetron; Postoperative Nausea and Vomiting; Quinuclidines; Serotonin Antagonists; Treatment Outcome | 2009 |
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Health Status Indicators; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quality of Life; Quinuclidines; Serotonin Antagonists; Surveys and Questionnaires; Vomiting; Young Adult | 2011 |
Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Topics: Adult; Antiemetics; Antineoplastic Agents; Aprepitant; Databases, Factual; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Logistic Models; Male; Middle Aged; Morpholines; Multivariate Analysis; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2011 |
[The efficacy of aprepitant and palonosetron on cisplatin doublet in lung cancer].
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Female; Humans; Isoquinolines; Lung Neoplasms; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Vomiting | 2011 |
[Comparison of antiemesis effects of granisetron, aprepitant and dexamethasone to palonosetron, aprepitant and dexamethasone in treatment of high-emetic risk chemotherapy-induced nausea and vomiting - a retrospective study for efficacy and safety in a sin
Topics: Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Combinations; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Risk; Vomiting | 2013 |
Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study.
Topics: Adult; Aged; Antiemetics; Aprepitant; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Isoquinolines; Lymphoma; Male; Middle Aged; Morpholines; Multiple Myeloma; Nausea; Palonosetron; Pilot Projects; Quality of Life; Quinuclidines; Transplantation, Autologous; Vomiting | 2014 |
Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Benzimidazoles; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Japan; Male; Middle Aged; Morpholines; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Vomiting | 2014 |
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dexamethasone; Drug Therapy, Combination; Female; Gemcitabine; Granisetron; Humans; Isoquinolines; Kidney Neoplasms; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vomiting | 2015 |
Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Topics: Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Combinations; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Oxonic Acid; Palonosetron; Prospective Studies; Quality of Life; Quinuclidines; Stomach Neoplasms; Surveys and Questionnaires; Tegafur; Vomiting | 2016 |
Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Bridged Bicyclo Compounds, Heterocyclic; Catheterization, Peripheral; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Liver; Liver Neoplasms; Male; Middle Aged; Morpholines; Nausea; Oxazines; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2016 |
Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2016 |
Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazine; Dexamethasone; Drug Therapy, Combination; Female; Glioma; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Temozolomide; Vomiting | 2016 |
Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Dexamethasone; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Morpholines; Nausea; Paclitaxel; Palonosetron; Prospective Studies; Quinuclidines; Vomiting; Young Adult | 2017 |
A Novel Mechanism of Endoplasmic Reticulum Stress- and c-Myc-Degradation-Mediated Therapeutic Benefits of Antineurokinin-1 Receptor Drugs in Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Aprepitant; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Extracellular Signal-Regulated MAP Kinases; Humans; Mice; Mice, Nude; Neurokinin-1 Receptor Antagonists; Piperidines; Proto-Oncogene Proteins c-myc; Quinuclidines; Signal Transduction; Survival Rate; Transplantation, Heterologous | 2021 |
Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cost-Benefit Analysis; Emetics; Humans; Internationality; Nausea; Palonosetron; Quinuclidines; Vomiting | 2022 |
Effectiveness of Palonosetron, 1-Day Dexamethasone, and Aprepitant in Patients Undergoing Carboplatin-Based Chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carboplatin; Dexamethasone; Humans; Isoquinolines; Nausea; Palonosetron; Quinuclidines; Vomiting | 2023 |